A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment

Aberrant activation of fibroblast growth factor receptor (FGFR) signalling contributes to progression and metastasis of many types of cancers including breast cancer. Accordingly, FGFR targeted tyrosine kinase inhibitors (TKIs) are currently under development. However, the efficacy of FGFR TKIs in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Jinho, Choi, Yoon Ji, Seo, Bo Yeon, Jo, Ukhyun, Park, Serk In, Kim, Yeul Hong, Park, Kyong Hwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584658/
https://www.ncbi.nlm.nih.gov/pubmed/31217507
http://dx.doi.org/10.1038/s41598-019-45278-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584658/
https://www.ncbi.nlm.nih.gov/pubmed/31217507
http://dx.doi.org/10.1038/s41598-019-45278-w

Ejemplares similares